Analyst Ratings February 9, 2026

Wolfe Research Elevates Cushman & Wakefield to Outperform, Sees Double-Digit Upside

Analyst lift follows valuation gap signal and accompanies leadership hires and a reaffirmed peer rating

By Marcus Reed CWK
Wolfe Research Elevates Cushman & Wakefield to Outperform, Sees Double-Digit Upside
CWK

Wolfe Research upgraded Cushman & Wakefield (NYSE: CWK) from Peerperform to Outperform, assigning a $19.00 price target that implies roughly an 18% total return to year-end 2026. The firm cites what it views as an attractive valuation and growth profile, noting the stock's low PEG ratio and an apparent gap between historical pricing and forward expectations. Other market participants have echoed bullish signals while the company has added senior leaders aimed at supporting growth and higher-margin businesses.

Key Points

  • Wolfe Research upgraded CWK from Peerperform to Outperform and set a $19.00 price target.
  • The $19.00 target implies roughly an 18% total return potential for shareholders to year-end 2026; CWK is trading at a PEG ratio of 0.11 and appears undervalued versus its Fair Value estimate.
  • Citizens reaffirmed a Market Outperform rating with a $19.00 target, and Cushman & Wakefield appointed Gregg Metcalf (Executive Director), Joey Verrant (COO, Asset Services Multifamily) and Andy Jansen (President, Project & Development Services) to strengthen leadership and pursue higher-margin activity.

Wolfe Research upgraded Cushman & Wakefield (NYSE: CWK) from Peerperform to Outperform on Monday and set a $19.00 price target. The research house said the move reflects an "attractive valuation and growth profile relative to the rest of our coverage," signaling that it sees untapped upside in the real estate services firm.

Wolfe highlighted valuation metrics that, in its view, underpin the upgrade. Data show CWK trading at a PEG ratio of 0.11, and the stock appears undervalued when compared with its Fair Value estimate. Based on Wolfe's $19.00 target for year-end 2026, the firm calculates approximately an 18% total return potential for Cushman & Wakefield shareholders from current levels.

The research note argues that the market is currently "pricing in more historical rather than forward performance," meaning investors may be focusing on past results instead of expected future improvements. Wolfe says that this disconnect between present valuation and anticipated forward performance creates a buying opportunity, a key rationale for raising its rating.

Market watchers have not been unanimous but there are corroborating views. Citizens has reiterated a Market Outperform rating on the company and also maintains a $19.00 price target. Citizens cited Cushman & Wakefield's ongoing actions to strengthen its balance sheet and increased activity in higher-margin business lines as factors supporting its stance.

Alongside the analyst coverage, Cushman & Wakefield has made several senior appointments intended to bolster its leadership bench and support growth. Gregg Metcalf has joined the firm as Executive Director, bringing more than 30 years of experience in real estate advisory services. Joey Verrant has been named Chief Operating Officer of Asset Services Multifamily, a role in which he will oversee operations and execution of strategy in that business line. Andy Jansen has taken on the role of President of Project & Development Services, focused on growth strategies across the Americas.

Wolfe's upgrade and Citizens' reaffirmation together highlight analyst attention on valuation, balance-sheet progress and the mix shift toward higher-margin lines. The firm-level commentary frames the current share price as reflecting historical performance metrics more heavily than anticipated future results, and it is that perceived mispricing that Wolfe says opens a buying window for investors.


Context limitations: The available reporting confines its conclusions to the valuation metrics, price targets and recent executive hires noted above. It does not provide additional operational performance figures or forward financial guidance from the company itself.

Risks

  • The market may continue to price the stock based on historical performance rather than anticipated forward improvements, reducing the near-term impact of analyst upgrades.
  • Planned balance-sheet strengthening and growth in higher-margin business lines may not materialize to the extent expected, which could limit upside.
  • New executive appointments are intended to support growth and execution, but their effectiveness and impact on financial results are not guaranteed by the reporting.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026